3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
2
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Lymphoid
2
Genitourinary
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
15
Lung Neoplasms
5
Neoplasms
4
Neoplasm Metastasis
4
Hematologic Neoplasms
3
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Lymphoproliferative Disorders
2
Lymphoma, Large-Cell, Anaplastic
2
Breast Neoplasms
2
Brain Neoplasms
2
Thyroid Neoplasms
1
Sexual Dysfunction, Physiological
1
Sarcoma
1
Rare Tumour
1
Rare Tumor
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroblastoma
1
Lymphoma
1
Glioblastoma
1
Genomic Instability
1
Gastrointestinal Neoplasms
1
Eunuchism
1
Erectile Dysfunction
1
Disease Resistance
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
Rituximab
5
fludarabine
4
Tacrolimus
4
Epoetin Alfa
4
Cyclophosphamide
4
Busulfan
4
Darbepoetin alfa
3
Alemtuzumab
3
fludarabine phosphate
2
entrectinib
2
atezolizumab
2
alectinib
2
Thiotepa
2
Therapeutics
2
Radiotherapy
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methotrexate
2
Etoposide
2
Early Intervention, Educational
2
Cytarabine
2
Bortezomib
2
Antilymphocyte Serum
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
venetoclax
1
trametinib
1
tirbanibulin
1
sargramostim
1
plerixafor
1
phenethyl isothiocyanate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
OTHER
×
Lymphoproliferative Disorders
×
alectinib
×
Clear all
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled
NCT05770037
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled